ES2181443T3 - Nuevos derivados de 3,3-difenilpropilaminas. - Google Patents
Nuevos derivados de 3,3-difenilpropilaminas.Info
- Publication number
- ES2181443T3 ES2181443T3 ES99924929T ES99924929T ES2181443T3 ES 2181443 T3 ES2181443 T3 ES 2181443T3 ES 99924929 T ES99924929 T ES 99924929T ES 99924929 T ES99924929 T ES 99924929T ES 2181443 T3 ES2181443 T3 ES 2181443T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- substituted
- unsubstituted
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000005359 phenoxyalkyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical class C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000001302 tertiary amino group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Luminescent Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Saccharide Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98108608A EP0957073A1 (en) | 1998-05-12 | 1998-05-12 | Novel derivatives of 3,3-diphenylpropylamines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2181443T3 true ES2181443T3 (es) | 2003-02-16 |
Family
ID=8231918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99924929T Expired - Lifetime ES2181443T3 (es) | 1998-05-12 | 1999-05-11 | Nuevos derivados de 3,3-difenilpropilaminas. |
Country Status (32)
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0957073A1 (en) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE29923134U1 (de) * | 1999-11-16 | 2000-06-29 | Schwarz Pharma Ag, 40789 Monheim | Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen |
| SE9904850D0 (sv) * | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
| DE10028443C1 (de) * | 2000-06-14 | 2002-05-29 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen |
| DE10033016A1 (de) * | 2000-07-07 | 2002-01-24 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| DE10315878B4 (de) * | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| WO2004091597A2 (en) * | 2003-04-15 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Method of treating irritable bowel syndrome (ibs) |
| EP1620389A1 (en) | 2003-04-25 | 2006-02-01 | Pharmacia & Upjohn Company LLC | Halogen substituted 3,3-diphenylpropylamines (tolterodine) having antimuscarinic activity |
| US7141696B2 (en) | 2003-05-23 | 2006-11-28 | Bridge Pharma, Inc. | Smooth muscle spasmolytic agents |
| WO2005012227A2 (en) * | 2003-08-05 | 2005-02-10 | Ranbaxy Laboratories Limited | Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine |
| WO2007039918A1 (en) * | 2005-10-06 | 2007-04-12 | Natco Pharma Limited | Novel process for the preparation of tolterodine |
| CA2634019A1 (en) * | 2005-12-20 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist |
| US8119667B2 (en) * | 2005-12-29 | 2012-02-21 | Schering-Plough Animal Health Corporation | Carbonates of fenicol antibiotics |
| PL2029567T3 (pl) * | 2006-05-24 | 2011-01-31 | Pfizer Ltd | Sposób wytwarzania pochodnych benzopiran-2-olu |
| AU2007267371B2 (en) * | 2006-05-31 | 2012-09-20 | Schwarz Pharma Ltd. | New synthesis of substituted hydroxymethyl phenols |
| EP1862449A1 (en) * | 2006-05-31 | 2007-12-05 | Schwarz Pharma Ltd. | A shortened synthesis of substituted hydroxymethyl phenols |
| IES20060424A2 (en) * | 2006-06-08 | 2007-10-31 | Schwarz Pharma Ltd | Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters |
| EP2004592B1 (en) * | 2006-06-09 | 2010-08-11 | Schwarz Pharma Ltd. | Synthesis of phenolic esters of hydroxymethyl phenols |
| BRPI0712865B1 (pt) * | 2006-06-09 | 2021-08-17 | Schwarz Pharma Ag | Composição farmacêutica estabilizada compreendendo fesoterodina, método para preparação da mesma e uso de uma substância |
| US7807715B2 (en) | 2006-06-09 | 2010-10-05 | Ucb Pharma Gmbh | Pharmaceutical compositions comprising fesoterodine |
| EA018376B1 (ru) * | 2006-06-12 | 2013-07-30 | Шварц Фарма Аг | Новые хиральные промежуточные продукты, способ их получения и их применение в производстве толтеродина, фезотеродина или их активных метаболитов |
| IES20060435A2 (en) | 2006-06-12 | 2007-12-12 | Schwarz Pharma Ltd | Shortened synthesis using paraformaldehyde or trioxane |
| CZ2006506A3 (cs) * | 2006-08-09 | 2007-10-03 | Zentiva, A. S. | Farmaceutická kompozice s obsahem tolterodinu |
| JP4859255B2 (ja) * | 2006-11-17 | 2012-01-25 | 旭化成ケミカルズ株式会社 | イソシアネートの製造方法 |
| TW200844080A (en) | 2007-01-11 | 2008-11-16 | Asahi Kasei Chemicals Corp | Process for producing isocyanate |
| WO2008144602A1 (en) * | 2007-05-18 | 2008-11-27 | Auspex Pharmaceuticals, Inc. | Deuterated zamifenacin derivatives |
| WO2009006413A1 (en) * | 2007-06-30 | 2009-01-08 | Auspex Pharmaceuticals, Inc. | Substituted pyrrolidines |
| US20090062398A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched tolterodine |
| US20090062385A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched fesoterodine |
| WO2009037569A2 (en) * | 2007-09-21 | 2009-03-26 | Actavis Group Ptc Ehf | An improved process for the preparation of fesoterodine |
| US20100297241A1 (en) * | 2007-10-01 | 2010-11-25 | Actavis Group Ptc Ehf | Amorphous Fesoterodine Fumarate |
| SG185939A1 (en) * | 2007-11-01 | 2012-12-28 | Acucela Inc | Amine derivative compounds for treating ophthalmic diseases and disorders |
| EP2294047A2 (en) * | 2008-04-04 | 2011-03-16 | Actavis Group PTC EHF | Novel mandelate salt of fesoterodine |
| BRPI0822695B1 (pt) | 2008-05-15 | 2017-05-02 | Asahi Kasei Chemicals Corp | processo para produzir um isocianato |
| CN102026965B (zh) | 2008-05-15 | 2014-02-26 | 旭化成化学株式会社 | 异氰酸酯的制造方法 |
| US20110171274A1 (en) * | 2008-07-21 | 2011-07-14 | Actavis Group Ptc Ehf | Fesoterodine Substantially Free of Dehydroxy Impurity |
| JP5381086B2 (ja) * | 2008-10-06 | 2014-01-08 | 日本電気株式会社 | 通信システム及び通信制御方法 |
| KR20120014583A (ko) | 2009-05-11 | 2012-02-17 | 라티오팜 게엠베하 | 타르타르산 염 형태의 데스페소테로딘 |
| IT1394219B1 (it) | 2009-05-15 | 2012-06-01 | Chemi Spa | Metodo di preparazione di fesoterodina fumarato di elevata purezza. |
| IT1394217B1 (it) | 2009-05-15 | 2012-06-01 | Chemi Spa | Metodo di preparazione di fesoterodina e/o fesoterodina fumarato. |
| EP2281801B1 (en) | 2009-07-27 | 2014-01-08 | Crystal Pharma, S.A.U. | Process for obtaining 3,3-diphenylpropylamines |
| IT1396373B1 (it) * | 2009-10-29 | 2012-11-19 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina. |
| EP2316432A1 (de) | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
| US20110124903A1 (en) * | 2009-11-20 | 2011-05-26 | Actavis Group Ptc Ehf | Solid state forms of fesoterodine intermediates |
| IT1397521B1 (it) | 2009-12-21 | 2013-01-16 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina con un basso contenuto di impurezze. |
| EP2364966A1 (en) | 2010-03-09 | 2011-09-14 | LEK Pharmaceuticals d.d. | Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-3-phenylpropylamines, intermediates for making hydroxytolterodine |
| EP2549985A1 (en) | 2010-03-22 | 2013-01-30 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
| WO2011125763A1 (ja) | 2010-03-31 | 2011-10-13 | 小野薬品工業株式会社 | 手足症候群の予防および／または治療剤 |
| JP5812500B2 (ja) | 2010-04-30 | 2015-11-17 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規なβ３アドレナリン作動性受容体アゴニスト |
| US20110282094A1 (en) | 2010-05-11 | 2011-11-17 | Intas Pharmaceuticals Limited | Process for preparation of phenolic monoesters of hydroxymethyl phenols |
| IT1401451B1 (it) | 2010-06-10 | 2013-07-26 | Chemi Spa | Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo. |
| WO2011158257A1 (en) | 2010-06-18 | 2011-12-22 | Panacea Biotec Ltd | Preparation process of fesoterodine and intermediates |
| WO2012025941A2 (en) | 2010-08-25 | 2012-03-01 | Cadila Healthcare Limited | Processes for the preparation of fesoterodine |
| US8492422B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
| IT1403094B1 (it) | 2010-12-09 | 2013-10-04 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina o un suo sale |
| WO2012098560A2 (en) * | 2011-01-17 | 2012-07-26 | Msn Laboratories Limited | Process for the preparation of muscarinic receptor antagonist |
| TWI590821B (zh) | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
| WO2012137047A1 (en) | 2011-04-07 | 2012-10-11 | Alembic Pharmaceuticals Limited | A process for preparing fesoterodine |
| EP2508175A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof |
| EP2508173A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Stabilized pharmaceutical composition comprising fesoterodine |
| WO2013021343A1 (en) | 2011-08-05 | 2013-02-14 | Ranbaxy Laboratories Limited | Process for the optical resolution of () -3- (2 -benzyloxy- 5 - bromophenyl) - 3 - phenylpropionic |
| WO2013046135A1 (en) | 2011-09-26 | 2013-04-04 | Ranbaxy Laboratories Limited | Process for the preparation of fesoterodine or its salts |
| US20140378699A1 (en) | 2012-01-07 | 2014-12-25 | Alembic Pharmaceuticals Limited | Process for the preparation of fesoterodine |
| CN103304356B (zh) * | 2012-03-12 | 2016-01-20 | 北京乐威泰克医药技术有限公司 | 羟胺的合成方法 |
| WO2013113946A2 (en) | 2012-05-04 | 2013-08-08 | Crystal Pharma, S.A.U. | Process for the preparation of optically active 3,3-diphenylpropylamines |
| WO2013046194A2 (en) | 2012-05-18 | 2013-04-04 | Alembic Pharmaceuticals Limited | The novel reference markers for fesoterodine fumarate |
| CA2875342C (en) | 2012-06-14 | 2017-06-13 | Ratiopharm Gmbh | Desfesoterodine salts |
| ITMI20121232A1 (it) * | 2012-07-16 | 2014-01-17 | Cambrex Profarmaco Milano Srl | Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati |
| CZ2014400A3 (cs) | 2014-06-09 | 2015-12-16 | Zentiva, K.S. | Stabilizovaná formulace fesoterodinu |
| US9751828B2 (en) | 2014-07-30 | 2017-09-05 | Dipharma Francis S.R.L. | Antimuscarinic compound having a low content of impurities |
| TR201721437A2 (tr) | 2017-12-25 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE766207C (de) | 1940-07-08 | 1952-12-22 | Ig Farbenindustrie Ag | Verfahren zur Herstellung von basischen Verbindungen der Diarylmethanreihe |
| DE925468C (de) | 1941-08-13 | 1955-03-21 | Hoechst Ag | Verfahren zur Herstellung von ª†, ª†-Diaryl-propyl-aminen |
| GB624117A (en) | 1946-12-07 | 1949-05-27 | Wellcome Found | Improvements in and relating to the preparation of substituted allylamines and propylamines |
| GB627139A (en) | 1947-05-28 | 1949-07-29 | Wellcome Found | Improvements in and relating to the preparation of quaternary ammonium salts of substituted propanolamines, allylamines and propylamines |
| NL70759C (enExample) | 1947-10-28 | |||
| US2567245A (en) * | 1948-05-10 | 1951-09-11 | Schering Corp | Aryl-(2-pyridyl)-amino alkanes and their production |
| US2556636A (en) * | 1948-06-23 | 1951-06-12 | Schering Corp | gamma-substituted propylamine type antihistamines |
| CH285388A (de) | 1948-11-09 | 1952-08-31 | Michael Dr Erlenbach | Verfahren zur Herstellung einer basischen Verbindung. |
| DE830193C (de) | 1948-11-09 | 1952-02-04 | Farbwerke Hoechst Vormals Meis | Verfahren zur Herstellung von basischen Verbindungen |
| GB685696A (en) | 1948-11-23 | 1953-01-07 | Schering Corp | Process for the manufacture of anti-histaminic compounds |
| NL74271C (enExample) | 1949-09-05 | |||
| US2676964A (en) * | 1950-06-07 | 1954-04-27 | Schering Corp | 3-pyridyl propylamine antihistamine substances |
| US3261841A (en) * | 1961-05-03 | 1966-07-19 | Sterling Drug Inc | N-substituted 1,5-iminocycloalkanes and -alkenes |
| US3216841A (en) * | 1962-04-30 | 1965-11-09 | Clevite Corp | Metal slip casting composition |
| DK111894A (enExample) | 1962-11-15 | |||
| GB1025041A (en) | 1964-02-21 | 1966-04-06 | Hoechst Ag | Process for the manufacture of diphenylalkylamines |
| GB1169944A (en) | 1966-08-25 | 1969-11-05 | Geistlich Soehne Ag | Novel 3,3-Diphenylpropylamines and processes for the preparation thereof |
| GB1169945A (en) * | 1966-08-25 | 1969-11-05 | Geistlich Soehne Ag | Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives |
| HU200591B (en) * | 1986-07-11 | 1990-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds |
| SE8800207D0 (sv) * | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| US5693144A (en) * | 1990-03-19 | 1997-12-02 | 3D Systems, Inc. | Vibrationally enhanced stereolithographic recoating |
| CA2132865C (en) | 1992-05-13 | 2003-12-02 | Eun S. Lee | Transdermal administration of oxybutynin |
| SE9203318D0 (sv) * | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| WO1996012477A1 (en) | 1994-10-21 | 1996-05-02 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
| AU728395B2 (en) | 1996-07-19 | 2001-01-11 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| JP2001505899A (ja) | 1996-12-12 | 2001-05-08 | デーデーエス ドラッグ デリバリー サービス ゲセルシャフト ツーア フェアデルング デア フォルシュング イン ファーマシューティッシャー テクノロジー ウント バイオファーマジー エムベーハー | 任意に活性物質を含むマトリクス材料−賦形剤コンパウンドの形態の処方物 |
| KR20000057548A (ko) * | 1996-12-13 | 2000-09-25 | 알프레드 엘. 미첼슨 | 광학적 전송물질 및 결합재 |
| SE9701144D0 (sv) | 1997-03-27 | 1997-03-27 | Pharmacia & Upjohn Ab | Novel compounds, their use and preparation |
| EP0872233A1 (en) | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
| AU8532798A (en) | 1997-06-13 | 1998-12-30 | Roland Bodmeier | Compounds which delay the release of active substances |
| EP0957073A1 (en) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| SE9802864D0 (sv) * | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| US6770295B1 (en) * | 1998-08-27 | 2004-08-03 | Pharmacia Ab | Therapeutic formulation for administering tolterodine with controlled release |
| SE9803871D0 (sv) * | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| DE19922662C1 (de) * | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
| CN100353935C (zh) * | 1999-11-11 | 2007-12-12 | 法马西雅公司 | 含托特罗定的药物制剂及其应用 |
| DE29923134U1 (de) * | 1999-11-16 | 2000-06-29 | Schwarz Pharma Ag, 40789 Monheim | Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen |
| SE9904850D0 (sv) * | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
| US6566537B2 (en) * | 1999-12-30 | 2003-05-20 | Pharmacia Ab | Process and intermediates |
| DE10028443C1 (de) | 2000-06-14 | 2002-05-29 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen |
| DE10033016A1 (de) * | 2000-07-07 | 2002-01-24 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen |
| US20030086972A1 (en) | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
| AR033711A1 (es) | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
| US20030027856A1 (en) | 2001-06-29 | 2003-02-06 | Aberg A.K. Gunnar | Tolterodine metabolites |
| GB0117619D0 (en) | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
| PL370539A1 (en) | 2001-09-04 | 2005-05-30 | Pfizer Inc. | Assay |
| EP1423092A2 (en) | 2001-09-05 | 2004-06-02 | Vectura Limited | Functional powders for oral delivery |
| IL160852A0 (en) | 2001-09-27 | 2004-08-31 | Pharmacia Ab | Pharmaceutical compositions for the treatment of urinary disorders |
| PT1461306E (pt) * | 2001-10-26 | 2009-04-01 | Pharmacia & Upjohn Co Llc | Compostos de amónio quaternário |
| US20030144352A1 (en) | 2001-11-05 | 2003-07-31 | Cammarata Sue K. | Antimuscarinic aerosol |
| AU2002360717A1 (en) * | 2001-12-20 | 2003-07-09 | Pharmacia Corporation | Controlled release dosage form having improved drug release properties |
| WO2003103637A2 (en) | 2002-01-10 | 2003-12-18 | Ranbaxy Laboratories Limited | Modified release, multiple unit drug delivery systems |
| KR100540035B1 (ko) | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
| DE10224107A1 (de) | 2002-05-29 | 2003-12-11 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz |
| ITMI20021329A1 (it) | 2002-06-14 | 2003-12-15 | Recordati Chem Pharm | Nuove ossialchilammine sostituite |
| WO2004019892A2 (en) | 2002-08-30 | 2004-03-11 | Watson Pharmaceuticals, Inc. | Drug delivery system for treating urinary incontinence |
| TW200408955A (en) * | 2002-09-30 | 2004-06-01 | Advent Networks Inc | Implementing request/reply programming semantics using publish/subscribe middleware |
| DE10315878B4 (de) * | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| EP1620389A1 (en) * | 2003-04-25 | 2006-02-01 | Pharmacia & Upjohn Company LLC | Halogen substituted 3,3-diphenylpropylamines (tolterodine) having antimuscarinic activity |
-
1998
- 1998-05-12 EP EP98108608A patent/EP0957073A1/en not_active Withdrawn
-
1999
- 1999-05-11 JP JP2000548284A patent/JP3929702B2/ja not_active Expired - Lifetime
- 1999-05-11 AU AU41412/99A patent/AU748057B2/en not_active Expired
- 1999-05-11 CA CA002328920A patent/CA2328920C/en not_active Expired - Lifetime
- 1999-05-11 BR BRPI9910406A patent/BRPI9910406B8/pt not_active IP Right Cessation
- 1999-05-11 HU HU0600760A patent/HU230434B1/hu unknown
- 1999-05-11 DE DE122007000065C patent/DE122007000065I2/de active Active
- 1999-05-11 US US09/700,094 patent/US6713464B1/en not_active Expired - Lifetime
- 1999-05-11 KR KR1020007012653A patent/KR100599004B1/ko not_active Expired - Lifetime
- 1999-05-11 PL PL99347823A patent/PL195581B1/pl unknown
- 1999-05-11 ES ES99924929T patent/ES2181443T3/es not_active Expired - Lifetime
- 1999-05-11 DK DK99924929T patent/DK1077912T3/da active
- 1999-05-11 IL IL13911099A patent/IL139110A0/xx active Protection Beyond IP Right Term
- 1999-05-11 RU RU2000125813/04A patent/RU2199525C2/ru active Protection Beyond IP Right Term
- 1999-05-11 PL PL380733A patent/PL218882B1/pl unknown
- 1999-05-11 AT AT99924929T patent/ATE220056T1/de active
- 1999-05-11 MX MXPA00011096A patent/MXPA00011096A/es unknown
- 1999-05-11 CN CNB998060380A patent/CN1207268C/zh not_active Expired - Lifetime
- 1999-05-11 DE DE69902037T patent/DE69902037T2/de not_active Expired - Lifetime
- 1999-05-11 CZ CZ20060029A patent/CZ299721B6/cs not_active IP Right Cessation
- 1999-05-11 HK HK02107859.3A patent/HK1046269B/zh not_active IP Right Cessation
- 1999-05-11 SK SK1547-2000A patent/SK286052B6/sk not_active IP Right Cessation
- 1999-05-11 PT PT99924929T patent/PT1077912E/pt unknown
- 1999-05-11 WO PCT/EP1999/003212 patent/WO1999058478A1/en not_active Ceased
- 1999-05-11 NZ NZ507487A patent/NZ507487A/xx not_active IP Right Cessation
- 1999-05-11 CZ CZ20003774A patent/CZ296605B6/cs not_active IP Right Cessation
- 1999-05-11 TR TR2000/03319T patent/TR200003319T2/xx unknown
- 1999-05-11 EP EP99924929A patent/EP1077912B1/en not_active Expired - Lifetime
- 1999-05-11 EP EP02013481A patent/EP1254890A1/en not_active Withdrawn
- 1999-05-11 PL PL380081A patent/PL202489B1/pl unknown
- 1999-05-11 CN CNB2005100702999A patent/CN100491336C/zh not_active Expired - Lifetime
- 1999-05-11 HU HU0100779A patent/HU226490B1/hu active Protection Beyond IP Right Term
-
2000
- 2000-10-17 IS IS5670A patent/IS2044B/is unknown
- 2000-10-17 ZA ZA200005728A patent/ZA200005728B/xx unknown
- 2000-11-10 NO NO20005669A patent/NO326872B1/no not_active IP Right Cessation
-
2004
- 2004-01-27 US US10/766,263 patent/US7230030B2/en not_active Expired - Lifetime
-
2005
- 2005-08-10 US US11/201,756 patent/US7384980B2/en not_active Expired - Fee Related
-
2006
- 2006-10-18 JP JP2006283861A patent/JP4658895B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-20 JP JP2007039857A patent/JP4833884B2/ja not_active Expired - Lifetime
- 2007-09-10 GE GEAP200710260A patent/GEP20084461B/en unknown
- 2007-09-13 NL NL300293C patent/NL300293I2/nl unknown
- 2007-09-14 LU LU91365C patent/LU91365I2/fr unknown
- 2007-10-04 FR FR07C0050C patent/FR07C0050I2/fr active Active
- 2007-10-15 CY CY2007024C patent/CY2007024I1/el unknown
-
2008
- 2008-04-17 US US12/105,016 patent/US7855230B2/en not_active Expired - Fee Related
-
2009
- 2009-07-17 NO NO2009015C patent/NO2009015I2/no unknown
-
2010
- 2010-06-14 US US12/814,982 patent/US7985772B2/en not_active Expired - Fee Related
-
2011
- 2011-06-15 US US13/161,049 patent/US8338478B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2181443T3 (es) | Nuevos derivados de 3,3-difenilpropilaminas. | |
| CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| CO4900056A1 (es) | Analogos de indazol sustituidos | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| ES2117155T3 (es) | Nuevas 3,3-difenilpropilaminas, su uso y su preparacion. | |
| CO5680403A2 (es) | Antagonistas de mchr1r | |
| UY25142A1 (es) | Antagonistas del receptor ccr-3 | |
| AR048282A1 (es) | Indol- o - glucosidos sustituidos | |
| AR023707A1 (es) | Un derivado de pirrolidina, uso del mismo, procesos para la preparacion del mismo y una composicion farmaceutica que lo comprende | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| CO5271658A1 (es) | Antagonistas del factor liberador de corticotropina | |
| CO4900032A1 (es) | Nuevos derivados de benzamidina | |
| ES2294313T3 (es) | Derivados de piridina como moduladores del receptor cb2. | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR009938A1 (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos | |
| ES2058265T3 (es) | Piperidinas antagonistas de opiaceos. | |
| UY24429A1 (es) | Acetidinas | |
| CO5640109A2 (es) | Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen | |
| CO5011117A1 (es) | 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos y procedimiento para su preparacion . | |
| ES2108595B1 (es) | Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion. | |
| ES2177275T3 (es) | Derivados de oxadiazolina y su uso como insecticidas. | |
| AR072336A1 (es) | Derivados de la 3-carboxipropil-aminotetralina, composiciones farmaceuticas que los contienen, procedimiento para su preparacion, intermediarios y su procedimiento de preparacion | |
| AR040140A1 (es) | Derivados de esteres de camptotecina en la posicion 20 | |
| AR016737A1 (es) | Procesos para preparar derivados indazol sustituidos | |
| ID25477A (id) | Turunan-turunan spiropiperidin |